A
Apollo Endosurgery
Less invasive therapies for the treatment of obesity
About Apollo Endosurgery
Apollo Endosurgery, Inc. is a medical technology company focused on revolutionizing patient care through the development of innovative endoscopic surgical products. The company specializes in minimally invasive procedures, particularly in the field of bariatrics, which deals with weight loss surgeries, and other gastrointestinal interventions. Apollo Endosurgery serves a diverse range of clients, including hospitals, clinics, and specialized medical practitioners across more than 80 countries.
Operating in the global healthcare market, Apollo Endosurgery targets the growing demand for less invasive surgical options. Their product portfolio includes devices like the Orbera Intragastric Balloon, which helps patients lose weight without the need for traditional surgery, and the OverStitch Endoscopic Suturing System, which allows for complex suturing procedures to be performed endoscopically (using a flexible tube inserted into the body).
The company's business model revolves around the development, manufacturing, and distribution of these medical devices. Revenue is generated primarily through the sale of these products to healthcare providers and medical institutions. Additionally, Apollo Endosurgery offers training and support services to ensure that medical professionals can effectively use their products, further enhancing their revenue streams.
Apollo Endosurgery is listed on the NASDAQ under the ticker symbol APEN, indicating its status as a publicly traded company. This listing provides the company with access to capital markets, enabling it to fund research and development, expand its product offerings, and enter new markets.
In summary, Apollo Endosurgery is a key player in the medical technology sector, focusing on innovative, minimally invasive surgical solutions that improve patient outcomes and reduce recovery times.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2006
- Headquarters
- Austin, United States
- Listing
- IPO 2005
- Employees
- 148
- Open positions
- None listed
- Dealroom signal
- 63.2/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Weight Management, Biomedical, Patient Care, Nutrition, Non-Invasive medical devices and treatments, Spinout, Metabolism, Biotech and Pharma
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest Sep 2016
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2022 | $615M | $615M | Boston Scientific | ↗ |
| POST IPO DEBTDebt | Dec 2021 | $35M | — | Innovatus Capital Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $75M | 0% |
| 2025 | $75M | 0% |
| 2024 | $75M | 0% |
| 2023 | $75M | 0% |
| 2022 | $75M | +24.3% |
| 2021 | $60M | +34.4% |
| 2020 | $45M | — |
Growth signals
Latest recorded traffic for Apollo Endosurgery is 410 monthly website visits, down 70.7% over the last three months. Apollo Endosurgery's team declined 44.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
PTV Healthcare Capital
HIG Capital
Remeditex Ventures
Novo Holdings- CPCPMG
Series B and later5 investors entered at this stage
Midcap Financial
Oxford Finance
UT Horizon Fund- CGCraig-Hallum Capital Group
Innovatus Capital Partners
Other known investors3 additional known investors
Boston Scientific
Johns Hopkins University
University of Texas Medical Branch
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Apollo Endosurgery on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Apollo Endosurgery’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







